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Introduction
Mastocytosis is characterized by an abnormal increase
of mast cells in the skin, lymph nodes, liver, spleen, and
bone marrow. Cutaneous mastocytosis is the most com-
mon form of mastocytosis, which presents as mast cell
hyperplasia limited to the skin [1,2]. Types of cutaneous
mastocytosis include urticaria pigmentosa, mastocy-
toma, diffuse and erythrodermic cutaneous mastocy-
tosis, and telangiectasia macularis eruptiva perstans
(Table 1). Urticaria pigmentosa is the most common
form and is characterized by oval or round red-brown
macules, papules, or plaques ranging in number from
a few to thousands. Symptoms of cutaneous mastocy-
tosis include pruritus, flushing, urticaria, and dermato-
graphism. Most patients have only skin involvement;
however, involvement may be systemic as well. Extra-
cutaneous involvement should be carefully considered
in adult patients with cutaneous mastocytosis. Symp-
toms of systemic mastocytosis include cutaneous symp-
toms in association with syncope, gastric distress,
nausea and vomiting, diarrhea, bone pain, neuropsy-
chiatric symptoms, and anaphylaxis.
The prevalence of mastocytosis in the general pop-
ulation is unknown. There are approximately 200,000
patients with mastocytosis in the US. The incidence 
of urticaria pigmentosa has been reported to be be-
tween 1 in 1,000 and 1 in 8,000 of the population at a
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dermatology clinic [3]. As many as 10% of patients with
urticaria pigmentosa will have systemic manifestations
with mast cell degranulation [4].
Mastocytosis is perceived as a medical manage-
ment dilemma because of its potential for unpre-
dictably heightened mast cell activity in response to
various physiologic states including pregnancy. We
report a case of mastocytosis in a pregnant woman
who achieved a successful pregnancy and delivery with
a healthy female baby.
Case Report
A 26-year-old, gravida 1, para 0, patient was seen at 27
weeks’ gestation with premature uterine contractions
and cutaneous manifestations of urticaria pigmentosa
with pruritus on the trunk and thighs. Her medical his-
tory revealed that the pruritus and flushing occurred on
her body when she was situated in a hot environment,
became tired and ate chocolate. These symptoms wors-
ened at the time of psychologic stress. She was diag-
nosed with cutaneous mastocytosis based on pathologic
examination of her skin biopsy 2 years previously. At the
same time, bone marrow biopsy was performed and
reported to be normocellular. Although regular medica-
tion with antihistamines was recommended at the time
of the diagnosis by the dermatologists, the patient had
never taken her drugs regularly. She had experienced an
allergic reaction once, with throat swelling and dizziness.
Although she did not require hospitalization, she took
2 days to recover. The agent responsible for the allergic
reaction remained unknown, since no drugs were taken.
The patient had had gastric symptoms such as heartburn
for 10 years. Endoscopic biopsy revealed antral gastritis.
On admission, no cervical dilatation was observed,
and uterine contractions were confirmed by external
tocodynamometry. She was initially recommended bed
rest and was hydrated with 1,000 mL of Ringer’s lactate
solution. Maternal corticosteroids were given (two do-
ses of intramuscular betamethasone 12 mg, 24 hours
apart) for fetal lung maturation. After sedation and
hydration, magnesium tocolysis was started because of
the persistent contractions. The patient was referred to
the dermatology department, and intravenous (IV) phe-
niramine maleate (50 mg per 2 mL) was administered.
After cutaneous manifestations were relieved and uter-
ine contractions stopped, she was discharged from the
hospital with the recommendation of regular check-
ups and oral pheniramine maleate (2 × 25 mg/day) as
well as multivitamin supplements containing vitamin
D, calcium and magnesium. She was also advised to
avoid factors that may exacerbate symptoms of the
disease.
The patient returned to our hospital at 40 weeks of
gestation with premature rupture of the membranes
and cutaneous manifestations of urticaria pigmentosa
and pruritus. The amniotic membrane had ruptured for
5 hours. On digital examination, the patient had a 1-cm
cervical dilation and 50% cervical effacement with a
pregnancy in cephalic presentation. Fetal heart rate
tracings were reactive, but uterine contractions were
minimal. Labor was stimulated by oxytocin. An antihis-
tamine agent (pheniramine maleate, 50 mg per 2 mL, IV)
and corticosteroid agent (dexamethasone, 8 mg per
2 mL, IV) to treat the symptoms, and an antibiotic agent
(cefazolin, 2 × 500 mg, IV) for prophylaxis of chorioam-
nionitis were administered. There were no complications
during labor. Labor pain was successfully managed with
warm showers, frequent position changes, and massage.
Since the patient did not require additional analgesia,
epidural analgesia was not carried out. After 6 hours
of labor, she gave birth to a healthy female infant via
normal spontaneous vaginal delivery with right medio-
lateral episiotomy. A local anesthetic agent (prilocaine
hydrochloride, 200 mg per 10 mL) was administered for
episiotomy. Neither local anesthetic agent nor antibiotic
agent caused any reaction. The postpartum period was
uneventful. The patient and her baby were discharged
from hospital 2 days after the delivery.
As a preventive measure, resuscitation equipment
was available during the labor, delivery, and postpartum
period. During pregnancy, the patient showed only cuta-
neous manifestations of urticaria pigmentosa and pru-
ritus on the trunk and thighs, but there was no other
exacerbation of the disease.
Discussion
The presence of too many mast cells, or mastocyto-
sis, can occur in two forms: cutaneous and systemic.
Table 1. Types of cutaneous mastocytosis
Mastocytoma Single or multiple macules, plaques or nodules
Urticaria pigmentosa Multiple macules, papules, and plaques
Diffuse and erythrodermic forms including bullous mastocytosis –
Telangiectasia macularis eruptiva perstans –
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Systemic mastocytosis comprises multiple distinct
entities in which mast cells infiltrate the skin and/or
other organs. The diagnosis of systemic mastocytosis
is made when an increased number of abnormal mast
cells is found during an examination of bone marrow.
Plasma and urinary levels of histamine and its metabo-
lites can assist the diagnosis, but do not correlate with
severity of the disease. The diagnosis of systemic masto-
cytosis is based on the presence of one major criterion
and one minor criterion or three minor criteria. The ma-
jor criteria include the presence of multifocal infiltrates
of more than 15 mast cells in the bone marrow and/
or other extracutaneous organs.The four minor criteria
include the presence of elevated serum alpha-tryptase
levels > 20 ng/mL, the expression of CD2 and CD25
surface markers in c-kit-positive mast cells from bone
marrow or other organs, the presence of c-kit muta-
tions on bone marrow and/or other tissues mast cells,
and the presence of > 25% abnormal spindle-shaped
mast cells in bone marrow and/or tissues [5]. Common
minor symptoms of systemic mastocytosis and histamine
release include weakness, fatigue, urticaria, pruritus,
flushing, abdominal cramps, vomiting, diarrhea, men-
tal confusion, and febrile episodes. Uncommon major
symptoms include grand mal seizures, anaphylaxis, and
cardiovascular collapse. It is surprising to note that
wheezing rarely accompanies these attacks [6–9].
Cutaneous mastocytosis is the most common form
of mastocytosis, predominantly affecting children, and
presents as mast cell hyperplasia limited to the skin. In
contrast to systemic mastocytosis, there are no well-
defined pathologic criteria for diagnosis of cutaneous
mastocytosis. This diagnosis is generally established by
an experienced physician after observation of typical
lesions of urticaria pigmentosa or mastocytoma. Skin
biopsies show increased numbers of mast cells (generally
more than 20 mast cells per high-power field) in the
absence of other inflammatory cells, particularly in the
upper dermis around blood vessels. The most common
cutaneous lesions in patients with mastocytosis are red-
brown macules, papules, and plaques of urticaria pig-
mentosa. The lesions of urticaria pigmentosa tend to be
the highest density on the trunk, although they may
affect all skin areas, including the mucous membranes.
The palms, soles, face, and scalp are often free of le-
sions. Flushing has been reported to occur in 17–36%
of patients with urticaria pigmentosa, although some
studies have failed to define the extent of systemic
manifestations [10]. Our patient’s symptoms were pru-
ritus and flushing; bone marrow biopsy was reported
to be normocellular, and skin biopsy revealed cutaneous
mastocytosis. Thus, the patient had only cutaneous
disease limited to the skin.
The symptoms of mastocytosis may be activated by
drugs (opioids, morphine, salicylic acid, codeine, alco-
hol, reserpine, amphotericin B, polymyxin B, pancuro-
nium, D-tubocurarine, and estrogen), exercise, hot and
cold weather, infections, moldy cheese, parasitosis,
snake, and bee venom. Our patient stated that her pru-
ritus and flushing were activated by hot weather and
physical exercise.
Despite our current understanding of mastocytosis,
there is little information on how pregnancy might
affect clinical features or tolerance of medications,
and outcomes of pregnant patients with mastocytosis.
Mast cells have estrogen and progesterone receptors
and thus are present in the myometrium and placenta,
are increased in number in the myometrium with preg-
nancy, and appear to affect the second stage of labor
[11–14]. Elevated levels of histamine have been
reported to increase pregnant myometrial contractions
in vitro, which may be associated with an increase in
preterm labor in vivo [15]. Mastocytosis is perceived as
a medical management dilemma because of its poten-
tial for unpredictably heightened mast cell activity in
response to various physiologic states including preg-
nancy. In addition, during labor and delivery, the stress
of labor and the medications given have the potential
for activating the disease. Therefore, there are many
potential complications of mastocytosis in pregnancy.
There are only a few studies of mastocytosis in preg-
nancy reported in the literature. Worobec et al [9]
described nine patients with systemic mastocytosis, who
delivered 11 infants with good outcomes, and found
that a subset of women with mastocytosis had exacer-
bated mastocytosis during and after pregnancy, but
labor and delivery progressed normally. Infants were
born generally healthy and were without mastocytosis.
Bruns and Hartmann [16] evaluated 12 pregnant
women with mastocytosis and reported that, during
pregnancy, four patients experienced deterioration of
mastocytosis symptoms, seven patients described no
change, and one patient had improved. The most fre-
quent symptoms that became worse during pregnancy
were an increase of cutaneous lesions, pruritus, dyspep-
sia, hypotension, and fatigue. In all 12 patients, there
were no significant complications during labor and deliv-
ery. In the present case, during pregnancy, cutaneous
manifestations of urticaria pigmentosa on the trunk and
thighs occurred, but there was no other exacerbation of
the disease. Labor and the postpartum period were also
uneventful. Villeneuve et al [17] reported the anesthetic
management of labor pain and cesarean section in a
patient with urticaria pigmentosa at risk for systemic
mastocytosis. They found that allergy testing prior to
pregnancy is important for the management of labor
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pain and anesthesia for cesarean section. Gupta et al
[18] also described the anesthetic management during
labor of a patient with urticaria pigmentosa. Kehoe et al
[19] reported a patient with indolent systemic masto-
cytosis using a doula for labor coaching. They con-
cluded that predelivery planning can help prepare staff
and patients for complications and that doulas can
assist with labor preparation and delivery using non-
medical approaches to relief of pain and delivery. Their
patient also experienced preterm labor at 24 weeks’
gestation. Donahue et al [15] described a woman with
telangiectasia macularis eruptiva migrans, a rare form
of cutaneous mastocytosis, and suggested that elevated
histamine excretion in a biopsy showing cutaneous mas-
tocytosis may be associated with preterm labor. The
present case also had preterm labor at 27 weeks’ gesta-
tion and was treated with magnesium tocolysis. García
Collada et al [20] and Notter et al [21] also reported
pregnant cases with mastocytosis. Table 2 shows cases
presenting with mastocytosis in pregnancy that have
been published in the English literature.
There is no cure for mastocytosis, and treatment is
aimed at relieving the symptoms. The treatment of mas-
tocytosis requires recognition of specific disease patterns
of involvement, with consequent institution of appro-
priate therapy based on the disease pattern manifested
in a patient. Antihistamine agents are used to decrease
pruritus and to treat gastric symptoms [7]. Conservative
intrapartum management can consist of prophylactic
H1 and H2 antihistamine therapy, IV epinephrine 
(1:10,000 dilution) and corticosteroids if required for
women with severe disease [9]. Good pain control may
contribute to a decrease in overall anxiety and help
reduce the risk of exacerbation of the disease. When
mast cell degranulation or anaphylaxis is suspected, cor-
ticosteroids, antihistamine drugs and epinephrine should
be used to prevent further mast cell degranulation and
cardiovascular collapse. Cesarean section is reserved for
obstetric indications. When surgery and general anes-
thesia are necessary, premedication with H1 and H2
antihistamine agents and with benzodiazepine to reduce
anxiety levels are recommended [8].
Finally, women with mastocytosis are fertile, and
pregnancy and delivery have been successful by block-
ing mast cell-mediated symptoms. However, clinicians
should be aware of preterm labor during pregnancy.
Symptomatic treatment aimed at reducing the effect of
mediators is effective with antihistamines and mast cell
stabilizing agents such as cromolyn sodium. To reduce
mast cell burden, interferon alpha, steroids and purine
analogs have been used with varying results. Future
directions for treatment include tyrosine kinase inhi-
bitors and bone marrow transplants [22]. Pregnant
women with mastocytosis should be treated sympto-
matically, and they should avoid factors that may exacer-
bate symptoms of the disease. As a preventive measure,
Table 2. Cases presenting with mastocytosis in pregnancy that have been published in the English literature
Author No. of cases
Clinical Complications in 
Delivery (wk)
characteristics pregnancy
Present case One Urticaria pigmentosa Pruritus, skin lesions, preterm 40
labor at 27 weeks
Villeneuve et al [17] One Urticaria pigmentosa No 36
Kehoe et al [19] One Systemic mastocytosis Preterm labor at 24 weeks 39
Bruns and 12 NA Four cases deteriorated, NA
Hartmann [16] seven cases did not change, 
and one case improved. No 
significant complications 
during labor and delivery
Worobec et al [9] Nine women, Five cutaneous Pruritus, skin lesions, Eight women 
11 pregnancies mastocytosis four abdominal cramps, carried fetuses to 
systemic mastocytosis dyspepsia term, 11 live infants
García Collada One NA NA NA
et al [20]
Gupta et al [18] One Urticaria pigmentosa No Full term
Donahue et al [15] One Telangiectasia macularis Preterm labor at 24 weeks 36
eruptiva perstans
Notter et al [21] One Urticaria pigmentosa NA NA
NA = not available.
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resuscitation equipment should be available during
labor, delivery and the postpartum period to treat
unanticipated hypotension and shock.
References
1. Metcalfe DD. Mastocytosis. In: Cecil RL, Plum F, Bennett JC,
eds. Cecil Textbook of Medicine, 20th edition. Philadelphia: WB
Saunders, 1996:1435–7.
2. Metcalfe DD. Classification and diagnosis of mastocytosis:
current status. J Invest Dermatol 1991;96:2S–4S.
3. Longley J, Duffy TP, Kohn S. The mast cell and mast cell 
disease. J Am Acad Dermatol 1995;32:545–61.
4. Vaughan ST, Jones GN. Systemic mastocytosis presenting
as profound cardiovascular collapse during anaesthesia.
Anaesthesia 1998;53:804–7.
5. Ionov ID. Mast cells and basophils in the reproductive 
function in women. Akushe Ginekol (Mosk) 1988;(11):9–12.
[In Russian]
6. Greenblatt EP, Chen L. Urticaria pigmentosa: an anesthetic
challenge. J Clin Anesth 1990;2:108–15.
7. Metcalfe DD. The treatment of mastocytosis: an overview. 
J Invest Dermatol 1991;96(Suppl 3):55S–56S.
8. Hosking MP, Warner MA. Sudden intraoperative hypoten-
sion in a patient with asymptomatic urticaria pigmentosa.
Anesth Analg 1987;66:344–6.
9. Worobec AS, Akin C, Scott LM, Metcalfe DD. Mastocytosis
complicating pregnancy. Obstet Gynecol 2000;95:391–5.
10. Kauma S, Huff T, Krystal G, Ryan J, Takacs P, Turner T. The
expression of stem cell factor and its receptor, c-kit, in human
endometrium and placental tissues during pregnancy. J Clin
Endocrinol Metab 1996;81:1261–6.
11. Castells MC. Mastocytosis: classification, diagnosis, and
clinical presentation. Allergy Asthma Proc 2004;25:33–6.
12. Soter NA. The skin in mastocytosis. J Invest Dermatol 1991;
96(3 Suppl):32S–38S.
13. Cunningham FG, MacDonald PC, Gant NF, Leveno KJ,
Gilstrap LC, Hankins GDV, Clark SL. Parturition. In:
Cunningham FG, MacDonald PC, Gant NF, Leveno KJ,
Gilstrap LC, Hankins GDV, Clark SL, eds. Williams Obstetrics,
20th edition. Stamford, CT: Appleton & Lange, 1997:
261–317.
14. Rudolph MI, Reinecke K, Cruz MA, Gallardo V, Gonzalez C,
Bardisa L. Distribution of mast cells and the effect of their
mediators on contractility in human myometrium. Br J Obstet
Gynaecol 1993;100:1125–30.
15. Donahue JG, Lupton JB, Golichowski AM. Cutaneous mas-
tocytosis complicating pregnancy. Obstet Gynecol 1995;85:
813–5.
16. Bruns SB, Hartmann K. Clinical outcomes of pregnant
women with mastocytosis. J Allergy Clin Dermatol 2003;
111(Suppl 2):S323.
17. Villeneuve V, Kaufman I, Weeks S, Deschamps A. Anesthetic
management of a labouring parturient with urticaria pig-
mentosa. Can J Anaesth 2006;53:380–4.
18. Gupta S, Gilder F, Glazebrook C. Intrapartum management
of a patient with urticaria pigmentosa. Int J Obstet Anesth
1998;7:261–2.
19. Kehoe SL, Bathgate SL, Macri CJ. Use of a doula for labor
coaching in a patient with indolent systemic mastocytosis
in pregnancy. Obstet Gynecol 2006;107:514–6.
20. García Collada JC, Pereda Marín RM, Miralles Serrano E,
Pacheco López JF. Epidural analgesia for labor in a patient
with systemic mastocytosis. Rev Esp Anestesiol Reanim 2000;
47:326–7. [In Spanish]
21. Notter A, Colomb D, Cosentino JL, Latarche M, Virieux C.
Mastocytosis and pregnancy: a case of urticaria pigmentosa.
Bull Fed Soc Gynecol Obstet Lang Fr 1969;21:455–6. [In French]
22. Greenhawt M, Akin C. Mastocytosis and allergy. Curr Opin
Allergy Clin Immunol 2007;7:387–92.
